Content deleted Content added
Juniperpaul (talk | contribs) m Reiterated the medication's name in the last sentence of initial paragraph, otherwise "it" would seem to refer to the larger kidney stone. |
rank, templates |
||
| (6 intermediate revisions by 5 users not shown) | |||
Line 1:
{{Short description|Medication}}
{{Use dmy dates|date=October 2021}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 461746753
| image = Tamsulosin.svg
2D structural formula of Tamsulosin wrong: Ethyl-Group like drawn in 3D Model.
| width = 250
| alt2 =
Line 21 ⟶ 23:
| legal_AU = S4
| legal_CA = Rx-only
| legal_CA_comment = <ref>{{cite web | title=Product monograph brand safety updates | website=Health Canada | date=February 2024 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database/label-safety-assessment-update/product-monograph-brand-safety-updates.html | access-date=24 March 2024}}</ref>
| legal_UK = POM
| legal_UK_comment = <ref>{{cite web | title=Flomaxtra XL, 400 micrograms, film-coated prolonged release tablet
| legal_US = Rx-only
| legal_US_comment = <ref>{{cite web | title=
<!--Pharmacokinetic data-->
Line 63 ⟶ 67:
}}
[[File:Tamsulosin - ARISTO Pharma - 0,4 mg Retardtabletten - Urologikum.jpg|thumb|Tamsulosin
<!-- Definition and medical uses -->
Line 72 ⟶ 76:
<!-- Society and culture -->
Tamsulosin was approved for medical use in the United States in 1997.<ref name=AHFS2018/> It is available as a [[generic medication]].<ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=767|edition=76}}</ref> In
== Medical uses ==
[[File:000636lg Flomax 0.4 mg.jpg|left|thumb|Flomax 0.4 mg oral capsule]]
Tamsulosin is primarily used for [[benign prostatic hyperplasia]] (BPH) and to help with the passage of [[kidney stone]]s.<ref>{{cite web | url = http://www.renalandurologynews.com/tamsulosin-aids-stone-expulsion/article/193855/ | title = Tamsulosin Aids Stone Expulsion | publisher = Renal and Urology News | date = 7 January 2011 | access-date = 4 October 2012 | archive-date = 14 May 2012 | archive-url = https://web.archive.org/web/20120514032753/http://www.renalandurologynews.com/tamsulosin-aids-stone-expulsion/article/193855/ | url-status = dead }}</ref><ref>{{cite web | url = http://www.prnewswire.com/news-releases/study-shows-use-of-tamsulosin-or-nifedipine-helps-patients-to-clear-ureteral-stone-fragments-faster-and-reduces-rate-of-recurrence-54518887.html | title = Study Shows Use of Tamsulosin or Nifedipine Helps Patients to Clear Ureteral Stone Fragments Faster and Reduces Rate of Recurrence }}</ref> Tamsulosin, however, appears to be effective only for stones over 4 mm and less than 10 mm in size.<ref name=Wang2016/>
Tamsulosin is also used as an add-on treatment for [[acute urinary retention]]. People may void more successfully after catheter removal if they are taking tamsulosin. People taking tamsulosin also are less likely to need recatheterization.<ref>{{cite journal | vauthors = Lucas MG, Stephenson TP, Nargund V | title = Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia | journal = BJU International | volume = 95 | issue = 3 | pages = 354–357 | date = February 2005 | pmid = 15679793 | doi = 10.1111/j.1464-410X.2005.05299.x | s2cid = 30254915 | doi-access = }}</ref>
Tamsulosin does not decrease the overall size of the prostate in men with BPH, and is not recommended for prevention of [[prostate cancer]].<ref name=":0">{{Cite book|title=Medical-surgical nursing : assessment and management of clinical problems| vauthors = Lewis SM, Dirksen SR, Heitkemper MM, Bucher LH |
=== Combination therapy ===
The results of the CombAT (combination of [[dutasteride]] (Avodart) and tamsulosin, under the brand name Duodart) trial in 2008 demonstrated that treatment with the combination of dutasteride and tamsulosin provides greater symptom benefits compared to monotherapy with either agent alone for treatment of benign prostatic hyperplasia.<ref name="Roehrborn2008">{{cite journal | vauthors = Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F | title = The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study | journal = The Journal of Urology | volume = 179 | issue = 2 | pages =
The CombAT trial became the medication [[Dutasteride/tamsulosin|Jalyn]]. It was approved by the FDA on 14 June 2010.<ref>[http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022460Orig1s000Approv.pdf FDA approval letter] at FDA.gov</ref> This combination can be useful because it may take up to six months for symptomatic relief to be found when using 5-alpha-reductase inhibitors such as dutasteride compared to alpha-1 receptor blockers, which can provide relief in some cases within 48 hours.<ref>Australian Medicines Handbook {{full citation needed|date=September 2016}}</ref>
Line 105 ⟶ 109:
Tamsulosin was first marketed in 1996 under the [[trade name]] Flomax. The U.S. patent expired in October 2009.<ref>{{cite web|title=Flomax – Big Patent Expirations of 2010|url=http://www.fiercepharma.com/special-reports/flomax-big-patent-expirations-2010|date=10 February 2010|access-date=14 January 2012|archive-date=22 April 2012|archive-url=https://web.archive.org/web/20120422163615/http://www.fiercepharma.com/special-reports/flomax-big-patent-expirations-2010|url-status=dead}}</ref> The [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) approved generics in March 2010.<ref>{{cite press release| url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm202728.htm| title = FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland| date = 2 March 2010| publisher=[[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA)}}</ref> In 2010, tamsulosin was available as OTC medication in UK.<ref>{{cite journal | vauthors = | title = OTC tamsulosin for benign prostatic hyperplasia | journal = Drug and Therapeutics Bulletin | volume = 48 | issue = 10 | pages = 113–116 | date = October 2010 | pmid = 20926447 | doi = 10.1136/dtb.2010.10.0052 | s2cid = 32141889 }}</ref>
It is marketed by various companies under licence, including [[Boehringer Ingelheim]] and [[CSL Limited|CSL]]. Tamsulosin hydrochloride extended-release capsules are marketed under the trade names Urimax 0.4 (India),Tamlocept 0.4 (India), Flomax, Flomaxtra, Contiflo XL, bestflo, Mecir LP (France), Urimax, Pamsvax, and Pradif,<ref>{{cite web|title=Pradif 0,4 Mg Capsule Rigide A Rilascio Prolungato |url=http://www.torrinomedica.it/farmaci/schedetecniche/PRADIF.asp |work=Torrinomedica.it|access-date=15 November 2012 | vauthors = Magnanelli S, Vetere AM }}</ref> although generic, unmodified-release capsules are still approved and marketed in many countries (such as [[Canada]]). Generic extended-release tablets are marketed in most countries of the [[European Economic Area|EEA]].<ref>{{cite web|title=Tamsulosina Mylan 0,4 mg cápsulas duras de liberación modificada EFG|url=http://cima.aemps.es/cima/pdfs/es/p/67279/67279_p.pdf|work=cima.aemps.es|access-date=29 October 2018 }}</ref> In [[Mexico]], it is marketed as Secotex and as Harnal D in [[Japan]] and [[Indonesia]] and as Harnal OCAS (oral controlled absorption system) in Thailand.<ref>{{cite web | title = Drugs.com Database | url= https://www.drugs.com/international/harnal-d.html}}</ref> In [[Egypt]],<ref>{{cite news |title= Novartis hits Astellas with transplant drug generic|url=https://www.reuters.com/article/americasRegulatoryNews/idUST34424920090811 |publisher= Reuters|date= 11 August 2009|access-date=11 August 2009}}</ref> [[Italy]], [[Russia]] and [[Iceland]], it is marketed under the trade name Omnic by Astellas Pharma Europe. The largest manufacturer of tamsulosin is Synthon BV (the Netherlands).
<div style="clear:both"></div>
Line 114 ⟶ 118:
{{Adrenergic receptor modulators}}
{{Portal bar | Medicine}}
{{Authority control}}
[[Category:Alpha-1 blockers]]
| |||